Literature DB >> 7772524

Desferrioxamine therapy accelerates clearance of iron deposits after bone marrow transplantation for thalassaemia.

C Giardini1, M Galimberti, G Lucarelli, P Polchi, E Angelucci, D Baronciani, D Gaziev, B Erer, G La Nasa, I Barbanti.   

Abstract

We treated 18 heavily iron-loaded patients who had become ex-thalassaemics after bone marrow transplantation with subcutaneous desferrioxamine therapy for 5-20 months. As determined using serum ferritin concentration, transferrin saturation and stainable liver iron obtained in follow-up biopsies, marked decreases in body iron stores were observed with this regimen. Moreover, the liver function tests demonstrate a trend to normalization in all cases. Local skin reactions to desferrioxamine were the only toxicities observed. We conclude that pharmacological iron chelation is a safe and effective therapy in the reduction of iron deposits in this clinical situation; it therefore represents a valid alternative to phlebotomy in selected patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7772524     DOI: 10.1111/j.1365-2141.1995.tb08426.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

Review 1.  Cure for thalassemia major - from allogeneic hematopoietic stem cell transplantation to gene therapy.

Authors:  Alok Srivastava; Ramachandran V Shaji
Journal:  Haematologica       Date:  2016-12-01       Impact factor: 9.941

Review 2.  Stem cell transplantation for thalassemia.

Authors:  Surapol Issaragrisil
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

3.  Hematopoietic cell transplantation for sickle cell disease: updates and future directions.

Authors:  Lakshmanan Krishnamurti
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 4.  A Short Review on Growth and Endocrine Long-term Complications in Children and Adolescents with β-Thalassemia Major: Conventional Treatment versus Hematopoietic Stem Cell Transplantation.

Authors:  Shayma Ahmed; Ashraf Soliman; Vincenzo De Sanctis; Nada Alaaraj; Fawzia Alyafei; Noor Hamed; Mohamed Yassin
Journal:  Acta Biomed       Date:  2022-08-31

5.  Iron overload in patients undergoing hematopoietic stem cell transplantation.

Authors:  Vinod Pullarkat
Journal:  Adv Hematol       Date:  2010-09-08

6.  Initial serum ferritin predicts number of therapeutic phlebotomies to iron depletion in secondary iron overload.

Authors:  Sandhya R Panch; Yu Ying Yau; Kamille West; Karen Diggs; Tamsen Sweigart; Susan F Leitman
Journal:  Transfusion       Date:  2014-09-11       Impact factor: 3.157

7.  Hepatic iron overload and fibrosis in patients with beta thalassemia major after hematopoietic stem cell transplantation: A pilot study.

Authors:  Ardeshir Ghavamzadeh; Mehrzad Mirzania; Naser Kamalian; Nahid Sedighi; Parisima Azimi
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2015-04-01

Review 8.  Prooxidant mechanisms in iron overload cardiomyopathy.

Authors:  Ching-Feng Cheng; Wei-Shiung Lian
Journal:  Biomed Res Int       Date:  2013-11-19       Impact factor: 3.411

9.  Outcome of iron reduction therapy in ex-thalassemics.

Authors:  Fouzia N Aboobacker; Gaurav Dixit; Kavitha M Lakshmi; Anu Korula; Aby Abraham; Biju George; Vikram Mathews; Alok Srivastava
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240

10.  Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children.

Authors:  J W Lee; H J Kang; E K Kim; H Kim; H Y Shin; H S Ahn
Journal:  Bone Marrow Transplant       Date:  2009-04-27       Impact factor: 5.483

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.